2011 Annual Meeting Brochure
2012 Annual Meeting in Tampa, FL, April 29-May 2
Finding Common Ground Across the Psychosis Spectrum
Previously, schizophrenia and bipolar disorder have been classified as two separate diagnoses in the practice of psychiatry. However, several findings recently have called into question whether these disorders are etiologically distinct. Family and twin studies have established that schizophrenia and bipolar disorder are familial and heritable phenotypes with shared genetic factors. Both disorders also share key clinical features including psychosis, neurocognitive impairment, and suicidality. During this presentation, Roy Perlis, MD, MSc will discuss recent findings in genetic studies of schizophrenia and bipolar disorder, as well as examine their implications on diagnostic tools and treatment. Plan to attend this session to gain insight into the future role of genetics in psychiatry.
2010 Tuesday Keynote Address
Dr. Peter Buckley
Dr. Henry Nasrallah
Antipsychotic Efficacy vs. Adverse Effects: Which Trumps? Point – Counterpoint
Tuesday, April 20, 9:00-11:00 AM
This session will provide a thorough and engaging discussion about the relative efficacy and tolerability profiles of the typical antipsychotic and the atypical antipsychotics, in the context of individualizing treatments for patients with schizophrenia.
The contemporary treatment of schizophrenia has (paradoxically) become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time there is still substantial debate and contention, fuelled by recent large pragmatic trials in schizophrenia, that the balance of efficacy and tolerability considerations remains complex and as yet inadequately predicted for the individual therapeutic context. Incorporating evidence from various sources on efficacy, safety, and tolerability, and developing effective and individualized strategies to improve therapeutic outcomes are key considerations.
To address these aspects, Drs. Peter Buckley and Henry Nasrallah will engage in a lively debate-designed to also engage our audience. Dr. Buckley is Professor and Chairman, Department of Psychiatry and Behavioral Health Medical College of Georgia in Augusta, while Dr. Nasrallah is a Professor of Psychiatry, Neurology and Neuroscience and Director of the Schizophrenia Research Program at the University of Cincinnati College of Medicine. This interactive session will provide a review of the available literature followed by a debate format between two well known clinical researchers regarding efficacy versus tolerability of antipsychotics in the treatment of schizophrenia.